From newly opened Phase 3 studies enrolling infants through adults to the first participants already dosed in the U.S. and Japan, Biogen shares an update on where its investigational salanersen program stands today.
Read their latest update here.
Do you like what you're reading?
Help make a difference in the lives of people affected by spinal muscular atrophy.